LRP Eligibility and Appointment: The COP-01 Duty List

1. Key takeaways

The local responsible person, or LRP, is the accountability hub of the Medical Device Administrative Control System (MDACS) and, in practice, the only workable application entry point open to an overseas manufacturer. The Medical Device Division (MDD) of the Department of Health recognises exactly 2 alternative eligibility routes: a legal entity incorporated in Hong Kong, China, or a natural person or legal entity holding a business registration in Hong Kong, China. There is no third route, no representative office shortcut and no reliance on a parent company elsewhere in the group. An appointment must be documented in a letter issued by the manufacturer itself.

The duty list sits in Code of Practice COP-01, the Code of Practice for Local Responsible Persons. Beyond the appointment formality, 4 core post-market obligations define the role: handling complaints, reporting adverse events, managing product recalls and keeping records available for inspection by the Medical Device Division. Each of the four is an operational capability rather than a declaration, and each has to survive an inspection rather than merely appear in a contract.

The structural point that manufacturers most often miss is that eligibility is cheap and performance is expensive. A business registration certificate satisfies the entry test; it says nothing about whether the holder can run a complaint log, a vigilance file and a recall simulation. Choosing an LRP on price therefore misprices the risk, because the obligations that follow appointment are the ones that generate exposure.

2. Legal basis

The eligibility rule is set out in the MDD publication Overview of the Medical Device Listing Process in Hong Kong, uploaded on 8 October 2025, under the applicant eligibility section, which requires the LRP to be a legal entity incorporated in Hong Kong, China, or a person or entity holding a business registration there. The responsibilities and operating requirements of the role are set out in COP-01, in its current version verified to 29 October 2026. The overview guidance is GN-01, Guidance Notes on Overview of the Medical Device Administrative Control System, updated and issued on 1 September 2026, with Chapter 3 addressing scope and Chapter 5 the application and approval process. Adverse event reporting by an LRP is governed by GN-03, Guidance Notes on Medical Incident Reporting by Local Responsible Persons, in its current version verified to 29 October 2026. MDD also publishes a one-page chart on the process and responsibilities of becoming an LRP.

Two features of this legal architecture deserve emphasis. First, none of it is subsidiary legislation; MDACS operates through published guidance notes and codes of practice, so the LRP obligations bind through the listing system, through procurement conditions and through contractual allocation rather than through a statutory penalty attached to the code itself. Second, the appointment letter is the instrument that transfers the relationship from the manufacturer to the local entity, which is why MDD treats it as the first required document in the application file.

3. Expert insights

An LRP is a responsible person, not an agency service. The official definition describes an entity designated by the manufacturer that carries the whole of the responsibility for dealing with MDD, for post-market obligations and for record keeping. Reading the role as a mail-forwarding or errand-running arrangement is the most common conceptual error made by overseas manufacturers during contract negotiation, and it is the origin of most later disputes. When a complaint arrives, the regulator does not ask who was supposed to act; it asks who is the LRP.

The entry threshold is low, but the continuing obligation is heavy. A single business registration certificate is enough to qualify. What follows covers complaints, adverse events, recalls and records, and requires a functioning quality management system behind those four processes. This combination of a low threshold and heavy obligation is the reason selection should be driven by demonstrated capability rather than by the quoted fee. A cheaper LRP that cannot produce a complaint trend analysis at inspection converts a saving into a listing risk.

The appointment letter is the core legal document. The official checklist places the manufacturer appointment letter for an LRP at the head of the required documents. That letter should state the scope of authority, the term of appointment, the conditions for termination and the boundary of responsibility. These four elements are not administrative niceties: they determine whether responsibility can be attributed and pursued after an incident, and whether a handover can be enforced when the relationship ends.

LRP status is tied to eligibility for the accelerated approval scheme. Paragraph 5 of the notes to the accelerated approval scheme provides that only an existing local responsible person is eligible to participate. In practical terms the LRP listing number is the ticket to the faster channel, so a manufacturer that intends to use that channel later has to secure LRP status earlier, not simultaneously.

Entity maintenance is a live obligation, not a one-off check. A business registration that lapses, an incorporated entity that is deregistered or a change of registered address all touch the eligibility foundation of a listing. Because the LRP is the applicant of record, an entity problem becomes a listing problem, and it surfaces at the least convenient moment, usually during a tender verification or an inspection.

4. Practical recommendations

• Write four elements into the appointment letter. Specify the scope of authority, the period of validity, the conditions for termination and handover, and the division of post-market duties with an information notification deadline for each.
• Verify the LRP entity before signing. Check the Hong Kong, China company incorporation and the validity of the business registration certificate, then agree an annual re-verification so that a lapse is detected by calendar rather than by incident.
• Build an information notification mechanism. Require the manufacturer to notify the LRP, within an agreed deadline, of recalls, adverse events and regulatory developments anywhere in the world, including markets that do not supply Hong Kong, China.
• Pre-set the replacement clause. A change of LRP involves a change of the listing applicant, so the contract should stipulate the handover procedure and a document transfer list in advance, rather than negotiating them during a dispute.
• Map each of the four obligations to a named process owner. Complaints, adverse events, recalls and records should each have a documented procedure, a responsible individual and a defined retention period.

5. Verification checklist

• □ LRP confirmed as a legal entity incorporated in Hong Kong, China, or as holding a valid business registration there.
• □ Manufacturer appointment letter signed and containing the four elements of scope, term, termination and responsibility boundary.
• □ LRP has established documented processes for complaints, adverse events, recalls and record keeping.
• □ Information notification deadlines from manufacturer to LRP agreed and recorded in the contract.
• □ Replacement and document handover clauses pre-set in the contract.
• □ LRP listing number obtained and recorded, as the precondition for accelerated approval scheme eligibility.
• □ Annual re-verification of incorporation status and business registration scheduled.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team coordinates local responsible persons, import and wholesale dealer licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com